Schizophrenia biomarkers found by GeneNews’ Sentinel Principle

A study using GeneNews’ (TSX:GEN) Sentinel Principle platform technology to identify complex changes in blood gene expression patterns that may be indicative of underlying risk factors for schizophrenia will be published in the American Journal of Medical Genetics Part B and is currently available online. “This study shows that we can identify a gene signature [...]

Rodman sees potential approval of ColonSentry in fourth quarter

In a meeting last week at the Rodman & Renshaw conference with Enzo Biochem (NYSE:ENZ), analyst Yigal Nochomovitz came away with an impression that feedback from New York State regulators “has been favorable” for Enzo’s bid to obtain approval for the GeneNews (TSX:GEN) ColonSentry molecular diagnostic test for assessing a patient’s current risk of having [...]

Enzo adds to Life Sciences team and products

Enzo Biochem (NYSE:ENZ) has added four experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications. Filling newly created positions is Bruce Taillon, as head of global technology business development, John Errico, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul [...]

Enzo reports on key discovery of novel targets

Scientists from Enzo Biochem’s (NYSE:ENZ) therapeutics group have presented a podium session entitled The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling at the WNT 2011 conference in Los Angeles. “Our scientific team has identified a new target on a key modulator of the Wnt system that not [...]

High Court declines to hear appeal from Life Technologies

The U.S. Supreme Court has refused to hear an appeal by Life Technologies (NASDAQ:LIFE) in a patent infringement suit brought by Enzo Biochem (NYSE:ENZ), which will enable Enzo to pursue its claim for damages against Applera Corp., now Life Technologies. The Supreme Court’s action leaves intact a decision from the Court of Appeals for the Federal [...]

Enzo to acquire rights to cervical cancer test

Enzo Biochem’s (NYSE:ENZ) clinical labs subsidiary has reached an agreement with IncellDx of Menlo Park, Calif. for the rights to market a proprietary laboratory test based on HPV OncoTect, an advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer. The test will further [...]

Personalized medicine is more than targeted therapeutics

That’s a message Enzo Biochem (NYSE:ENZ) wants to get out. “We are positioned extremely well for personalized medicine in the sense that as new immunoassays are recommended by the various professional societies, we are able to move them into the market very quickly because of our broad range of technology and licensure,” David Goldberg, VP [...]

Enzo backs utility of GeneNews test

In an interview with partneringNews, Kevin Krenitsky, President of Enzo Clinical Labs, a unit of Enzo Biochem (NYSE:ENZ), called GeneNews’ (TSX:GEN) ColonSentry pre-screening assay for colorectal cancer risk assessment a “benchmark example for the types of tests Enzo will be advancing.” GeneNews previously licensed ColonSentry to Enzo, which submitted the test for approval to New York [...]

Enzo gets positive feedback from GeneNews test

Rodman & Renshaw, in a new report that cites an Enzo Biochem (NYSE:ENZ) conference call, says that Enzo has initiated early marketing research and a roll-out strategy to assess interest among physicians and patients of GeneNews’ (TSX:GEN) ColonSentry test, “with a strong positive response for the new test.” GeneNews previously licensed ColonSentry to Enzo, which [...]

GeneNews partner readying ColonSentry submission

Enzo Biochem’s (NYSE:ENZ) clinical labs division has completed validation testing of the GeneNews (TSX:GEN) ColonSentry pre-screening test for colorectal cancer and is in the final stages of submitting the data package to New York State regulatory authorities, according to a new report by Rodman & Renshaw. Analyst Reni Benjamin writes that the validation “demonstrated consistency [...]